As of 2025-08-04, the Intrinsic Value of Citius Pharmaceuticals Inc (CTXR) is -14.53 USD. This CTXR valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.29 USD, the upside of Citius Pharmaceuticals Inc is -1,226.61%.
Based on its market price of 1.29 USD and our intrinsic valuation, Citius Pharmaceuticals Inc (CTXR) is overvalued by 1,226.61%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.53 - -14.53 | -14.53 | -1,226.61% |
| P/E | (52.09) - (53.25) | (54.50) | -4324.8% |
| DDM - Stable | (21.45) - (80.12) | (50.78) | -4036.7% |
| DDM - Multi | (16.80) - (50.66) | (25.45) | -2073.1% |
| Market Cap (mil) | 18.66 |
| Beta | 2.44 |
| Outstanding shares (mil) | 14.47 |
| Enterprise Value (mil) | 18.63 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.38% |
| Cost of Debt | 5.00% |
| WACC | 7.66% |